Joseph V. Gulfo Resigns as CEO of MELA Sciences; Robert C. Coradini Named Interim CEO; David Stone Elected Chairman of the

Joseph V. Gulfo Resigns as CEO of MELA Sciences; Robert C. Coradini Named
Interim CEO; David Stone Elected Chairman of the Board

IRVINGTON, N.Y., June 17, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc.
(Nasdaq:MELA), the medical device company that has developed MelaFind^®, today
announced that Joseph V. Gulfo has resigned as Chairman, President, Chief
Executive Officer, and member of the Board of Directors effective June 15,
2013. Robert C. Coradini, a member of the Board of Directors since December
2011, will serve as interim CEO while the board conducts a search for a new
CEO. Mr. Coradini has over 20 years experience in the health care industry
leading and managing businesses for Johnson & Johnson and GE Medical Systems
(currently known as GE Healthcare).

While at Johnson & Johnson, Mr. Coradini held numerous senior leadership
positions – he has been President of various subsidiaries of J&J, including
Lifescan, Cordis Endovascular and Cardiovations (Ethicon) and was the head of
business development of the Medical Devices & Diagnostics Group. He was most
recently President of New Ventures of the Johnson & Johnson Consumer Group of
Companies where he was responsible for the OrthoNeutrogena division (currently
known as Ortho Dermatologics), a leader in dermatology, which was acquired by
Valeant International.

"We are thankful for Joseph's leadership over the past nine years as the
company has undergone a successful transformation from product development, to
FDA Approval, to early commercial launch of MelaFind® in the US and Germany,"
said Mr. Coradini. "The Board and I believe in the technology as a major
advance for dermatologists in their fight against Melanoma. It is our intent
to work closely with these physicians to succeed.We wish Joseph the best in
the next phase of his career."

Upon this change, David K. Stone, who has served as Lead Independent Director,
will assume the role of Chairman of the board and will lead the search for Mr.
Gulfo's replacement.

About MELA Sciences

MELA Sciences, Inc. is a medical device company focused on the
commercialization of its flagship product, MelaFind®, and its further design
and development.MelaFind® is a first-in-class, FDA approved non-invasive tool
to provide additional information to dermatologists during melanoma skin
examinations. The device uses light from visible to near-infrared wavelengths
to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides
information on a lesion's level of morphologic disorganization to provide
additional objective information that may be used by dermatologists in the
biopsy decision-making process. MelaFind® has been approved by the US Food and
Drug Administration for use in the US. In addition, MelaFind® has received CE
Mark approval and is approved for use in the European Union.

For more information on MELA Sciences, Inc., visit www.melasciences.com

Cautionary Statement Regarding Forward Looking Statements

Safe Harbor: This press release includes "forward-looking statements" within
the meaning of the Securities Litigation Reform Act of 1995. These statements
include but are not limited to our plans, objectives, expectations and
intentions and other statements that contain words such as "expects,"
"contemplates," "anticipates," "plans," "intends," "believes," "assumes,"
"predicts" and variations of such words or similar expressions that predict or
indicate future events or trends, or that do not relate to historical matters.
These statements are based on our current beliefs or expectations and are
inherently subject to significant known and unknown uncertainties and changes
in circumstances, many of which are beyond our control. There can be no
assurance that our beliefs or expectations will be achieved. Actual results
may differ materially from our beliefs or expectations due to financial,
economic, business, competitive, market, regulatory and political factors or
conditions affecting the company and the medical device industry in general,
as well as more specific risks and uncertainties facing the company such as
those set forth in its reports on Forms 10-Q and 10-K filed with the U.S.
Securities and Exchange Commission (the "SEC"). Factors that might cause such
a difference include whether MelaFind® achieves market acceptance. Given the
uncertainties affecting companies in the medical device industry such as the
Company, any or all of these forward-looking statements may prove to be
incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. The Company urges you to carefully review and
consider the disclosures found in its filings with the SEC which are available
atwww.sec.gov and www.melasciences.com.

CONTACT: For Investors
         Lynn Pieper
         Westwicke Partners
         415-202-5678
        
         For Media
         Claudia Beqaj
         PR@melasciences.com